Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Astrazeneca Global R&D (China), Xizang North Road, Jing'an District, Shanghai 201203, China.
Drug Discov Today. 2024 Apr;29(4):103925. doi: 10.1016/j.drudis.2024.103925. Epub 2024 Feb 23.
The objectives of drug R&D in China have shifted toward innovation and globalization, highlighting the ecological imperative to involve innovative partner-like academic research organizations (AROs). AROs are led by academic institutions and, when compared to contract research organizations (CROs), their strengths lie in promoting academic excellence, knowledge sharing, independence, collaborative networks and industry partnerships. Our desk-based analysis shows that although the service scope of Chinese AROs is similar to that of AROs in the US, they lack experience in broad service provision for innovative drugs, institution-institutional platforms and industry partnerships. We make several suggestions about how to achieve the synergy of academic institutions and industry-based organizations in drug innovation by using a ARO-CRO hybrid service model.
中国的药物研发目标已经转向创新和全球化，这凸显了让具有创新能力的类似伙伴型学术研究机构（ARO）参与的生态必要性。ARO 由学术机构领导，与合同研究组织（CRO）相比，其优势在于促进学术卓越、知识共享、独立性、合作网络和行业伙伴关系。我们的案头分析表明，尽管中国 ARO 的服务范围与美国的 ARO 相似，但它们在为创新药物提供广泛服务、机构间平台和行业伙伴关系方面缺乏经验。我们提出了一些建议，通过使用 ARO-CRO 混合服务模式，实现学术机构和以产业为基础的组织在药物创新方面的协同作用。
